Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Inclusion Criteria

• •For subjects with LBCL:
• •Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017
• •At least 1 measurable lesion at time of enrollment
• •Relapsed or refractory disease after at least 2 lines of chemotherapy
• •Absence of significant donor (product)-specific anti-HLA antibodies (DSA) at screening (Note: Only applicable for Phase 2)
• •For subjects with CLL/SLL:
• •Diagnosis of CLL/SLL
• •Relapsed/refractory disease
• •Subjects relapsed/refractory to BTKi therapy and high-risk disease
• •Subjects relapsed/refractory with 2 or more lines of therapy including BTKi and BCL-2 inhibitor (venetoclax)
• •At least 1 measurable lesion at time of enrollment
• •For all subjects:
• •Male or female subjects ≥18 years of age
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
• •Adequate hematological, renal, and liver function